Physical inactivity has consistently been shown to be one of the most powerful, modifiable risk factors for all causes of death and disease, alongside smoking and obesity.
This interactive body map brings together scientific evidence on the links between lack of physical activity and disease.
Click on the coloured dots on the body, or choose a specific disease from the dropdown menu, or cycle through all diseases via the next and previous buttons.
To use the map, click on any of the coloured dots on the body, or choose a specific disease from the dropdown menu. You can also filter by disease or condition type.
This is the first in our package on the benefits of exercise. Read other articles in the package here.
For a copy of the data and notes on the methodology used for the calculations, please visit The Conversation’s GitHub page.
Carol Maher receives funding from the National Health and Medical Research Council and the National Heart Foundation.
Tim Olds receives funding from the ARC and the NHMRC.
This article was originally published on The Conversation. Read the original article.


Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
3 clinical-grade skincare creams you really shouldn’t buy online
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 



